All data files are available from the figshare database (accession number [10.6084/m9.figshare.12154896](https://doi.org/10.6084/m9.figshare.12154896)).

Introduction {#sec004}
============

Acute myocardial infarction (MI) is diagnosed with a combination of clinical symptoms, signs, electrocardiography, and acute elevation of biomarkers, such as creatinine kinase and troponin I. \[[@pone.0233178.ref001]\] Troponin I that was elevated due to myocardial injury from thrombus occlusion of epicardial coronary artery was defined as type 1 MI. However, troponin I was frequently found to be elevated from the conditions known as type 2 MI. It was related to myocardial oxygen supply and demand mismatch, coronary hypoperfusion from generalized hypotension such as septic shock, respiratory failure, pulmonary embolism and acute heart failure. \[[@pone.0233178.ref002]\] Previous studies found that patients with type 2 MI when admitted to intensive care unit (ICU) was associated with higher in-hospital mortality compared to those with type 1 MI. \[[@pone.0233178.ref003]--[@pone.0233178.ref005]\] Due to differences in the mechanisms that lead to myocardial injury, the definitive treatment for type 2 MI is an essential clinical issue. \[[@pone.0233178.ref005]\]

Aspirin reduced all-cause mortality by about one-sixth and vascular death by 15% in patients with occlusive coronary artery disease (i.e., type 1 MI) and multiple risk factors for atherosclerosis, such as diabetes mellitus, ischemic stroke, and peripheral arterial disease. \[[@pone.0233178.ref006]\] Adverse outcomes were further reduced by combination therapy with aspirin and P2Y12 inhibitors, such as clopidogrel and ticagrelor, in patients with type 1 MI. \[[@pone.0233178.ref007]\] However, the exact role of antithrombotic agents in patients with type 2 MI remains uncertain. We thus conducted this retrospective study to investigate the impact of these medications in patients with type 2 MI when admitted to non-cardiac ICU.

Methods {#sec005}
=======

Study population {#sec006}
----------------

For this retrospective study, we screened 2678 patients admitted to the ICU at Taipei Veterans General Hospital due to critical conditions and the requirement for intensive care between December 2015 and July 2017. Patients were admitted from the emergency room or transferred from the ordinary ward to the medical or surgical ICU (SICU). Patients with available serum troponin I at ICU admission were enrolled. We excluded patients whose ICU stays were \<3 days, those undergoing postsurgical monitoring or post--percutaneous coronary intervention monitoring and those with definite diagnosis of type 1 MI, i.e., symptoms of angina, plus new ischemic ECG changes and identification of thrombus occlusion of coronary artery by angiography. This study was conducted according to the principles of the Declaration of Helsinki and was approved by the Research Ethics Committee of Taipei Veterans General Hospital. All participants provided written informed consent. A flowchart of patient enrollment and classification is shown in [Fig 1](#pone.0233178.g001){ref-type="fig"}.

![Flow chart of patients enrollment.\
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Measurement of clinical variables {#sec007}
---------------------------------

We reviewed the medical records of each patient in detail after enrollment. Data were collected on patients' clinical characteristics, including age, sex, body weight, body mass index (BMI), comorbidities, etiologies of ICU admission, categories of chronic medication use, and disease severity. The acute physiology and chronic health evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores were calculated to evaluate disease severity in the first 24 hours after ICU admission. \[[@pone.0233178.ref008], [@pone.0233178.ref009]\] We reviewed clinical and microbiological data to collect information on infection foci. Blood chemistry parameters were measured and cell counts were determined by routine laboratory methods on the first day of ICU admission. The estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease equation. Serum troponin I level was measured by electrochemiluminescence immunoassay (Elecsys; Roche Diagnostics GmbH, Mannheim, Germany) using Cobas e 600 analyzer, for which the 99^th^ percentile of the upper reference limit value is 0.10 ng/mL. We stratified the study cohort according to the troponin I value, and compared the baseline characteristics of study subjects with troponin I levels \> 0.10 ng/mL with those with lower serum troponin I levels.

Identification of exposure to antithrombotic agents {#sec008}
---------------------------------------------------

We retrieved data on antithrombotic use from patients' electronic medical records. We divided patients with elevated troponin I into three groups according to anticoagulant medication; no, chronic and new prescription. We defined the chronic use of antithrombotic agents, including antiplatelet agents (e.g., aspirin, clopidogrel, ticlopidine, dipyridamole), direct oral anticoagulants, and vitamin K antagonists (e.g., warfarin) as prescription \>30 days before ICU admission. We also recorded new prescriptions and withdrawals of antithrombotics during the patients' ICU stays.

Study outcomes and patient follow-up {#sec009}
------------------------------------

We recorded short and long-term adverse events for the study sample. Short-term adverse events included the lengths of ICU stay and hospitalization, gastrointestinal tract bleeding during the ICU stay, acute renal failure requiring dialysis during the ICU stay, and in-hospital and 30-day mortality. Long-term adverse events included the prevalence of persistent ventilator dependence, dialysis dependence, and one-year mortality. The primary outcomes were 30-day and one-year mortality. Respiratory failure was defined as the need for endotracheal intubation and mechanical ventilator support. \[[@pone.0233178.ref010]\] Acute kidney injury (AKI) was defined as the acute deterioration of renal function and requirement for renal replacement therapy, according to the Acute Kidney Injury Network criteria. \[[@pone.0233178.ref011]\] Sepsis was defined as life-threatening organ dysfunction caused by dysregulated host response to infection, as reflected by a ≥2-point increase in the SOFA score. \[[@pone.0233178.ref012]\] Patients were followed until December 2018, with all-cause mortality, rehospitalization, and persistent ventilator or dialysis dependence recorded and analyzed.

Statistical analysis {#sec010}
--------------------

Categorical variables were expressed as numbers and percentages and compared using the chi-squared test. Continuous variables were expressed as means ± standard deviations and compared between groups using analysis of variance or the Mann--Whitney *U* test. For the comparison of survival rates of patients with different troponin I levels and the effect of antithrombotics among those with higher troponin levels, we used Kaplan--Meier survival curves and the log-rank test. Cox proportional-hazard regression analyses were performed to obtain hazard ratios (HRs) and associated 95% confidence intervals (CIs). Variables with *p* values \< 0.05 in the univariable regression analysis were entered in the multivariable regression analysis. Multivariable Cox regression analyses were performed for the whole study cohort and for patients with higher troponin I levels. Interactions between variables and chronic antithrombotic use were examined for one-year mortality. *P* values \< 0.05 were considered to be significant. All analyses were performed using SPSS software (version 19.0; IBM Corporation, Armonk, NY, USA).

Results {#sec011}
=======

Baseline characteristics and clinical outcomes stratified by troponin I level {#sec012}
-----------------------------------------------------------------------------

In total, 597 study subjects admitted to the ICU for \>3 days with available serum troponin I data were included in this study; 407 (68%) of these patients had elevated troponin I (\> 0.1 ng/mL) at ICU admission. Baseline characteristics of the study cohort are provided in [Table 1](#pone.0233178.t001){ref-type="table"}. Patients in the elevated troponin I group had higher APACHE II and SOFA scores, more hemodynamic instability, less percentage of post-operation, higher serum creatinine and lactate level, and lower platelet counts than did the rest of the cohort. Among underlying diseases, end-stage renal disease and chronic heart failure were more prevalent among patients in the elevated troponin I group.

10.1371/journal.pone.0233178.t001

###### General features of the patients, according to serum troponin I levels at ICU admission.
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                                       Overall (n = 597)   Troponin I ≤ 0.1 (n = 190)   Troponin I \> 0.1 (n = 407)   *P* value
  ------------------------------------ ------------------- ---------------------------- ----------------------------- -----------
  Age (year)                           70 ± 17             70 ± 16                      70 ± 17                       0.861
  Sex (male)                           385 (65)            129 (68)                     256 (63)                      0.271
  APACHE II                            27 ± 8              26 ± 8                       28 ± 8                        \<0.001
  SOFA                                 9 ± 3               8 ± 3                        10 ± 3                        \<0.001
  Admission diagnosis                                                                                                 
      Respiratory failure (%)          311 (52)            104 (55)                     207 (51)                      0.381
      hemodynamic unstable (%)         176 (30)            40 (21)                      136 (33)                      0.002
      Post operation (%)               64 (11)             35 (18)                      29 (7)                        \<0.001
  Focus of infection                                                                                                  
      Pneumonia (%)                    290 (49)            95 (50)                      195 (48)                      0.661
      Catheter related infection (%)   65 (11)             17 (9)                       48 (12)                       0.326
      Intraabdominal infection (%)     90 (15)             35 (18)                      55 (14)                       0.140
  Lab findings, Mean ± SD                                                                                             
      Troponin I (ng/ml)               1.32 ± 3.90         0.1 ± 0.0                    1.9 ± 4.6                     \<0.001
      Serum creatinine (mg/dl)         2.69 ± 2.20         2.34 ± 2.09                  2.86 ± 2.23                   0.009
      HCO3 (mmHg)                      20.9 ± 5.0          21.7 ± 4.7                   20.6 ± 5.0                    0.013
      Lactate (mg/dl)                  25 ± 26             17 ± 15                      29 ± 29                       \<0.001
      CRP (mg/dl)                      11.9 ± 5.4          14.5 ± 11.3                  12.3 ± 10.7                   0.172
  Underlying disease                                                                                                  
      Hypertension (%)                 319 (53)            105 (55)                     214 (53)                      0.597
      Diabetes mellitus (%)            221 (37)            67 (35)                      154 (38)                      0.585
      COPD (%)                         30 (5)              10 (5)                       20 (5)                        0.843
      ESRD (%)                         62 (10)             10 (5)                       52 (13)                       0.006
      CHF (%)                          80 (13)             17 (9)                       63 (16)                       0.029
      Prior history of CAD (%)         116 (19)            37 (20)                      79 (20)                       1.000
      Prior stroke (%)                 48 (8)              15 (8)                       33 (8)                        1.000
      Cancer (%)                       151 (25.3)          61 (32.1)                    90 (22.1)                     0.001
  Chronic medication use                                                                                              
      ACEI/ARB                         142 (23.8)          53 (27.9)                    89 (21.9)                     0.122
      beta-blocker                     117 (19.6)          40 (21.1)                    77 (18.9)                     0.580
      Statin                           76 (12.7)           20 (10.5)                    56 (13.8)                     0.294
      OHA                              115 (19.3)          26 (13.7)                    89 (21.9)                     0.019
      ATT                              148 (24.8)          48 (25.3)                    100 (24.6)                    0.539
  ATT during ICU admission             224 (37.5)          66 (34.7)                    158 (38.8)                    0.365

Values are given as mean and standard deviation or numbers and percentages.

APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; CRP, C reactive protein; COPD, chronic obstructive pulmonary disease; ESRD, end stage renal disease; CHF, congestive heart failure; CAD, coronary artery disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; OHA, oral hypoglycemic agents; ATT, anti-thrombotics.

Troponin I elevation was associated with increased 30-day and one-year mortality {#sec013}
--------------------------------------------------------------------------------

Short and long-term outcomes are summarized in [Table 2](#pone.0233178.t002){ref-type="table"}. A total of 209 (35%) patients died during hospitalization. Compared with critically ill patients without elevated troponin I levels, those with troponin I levels \> 0.1 ng/mL had higher incidences of in-hospital mortality (27% vs. 39%, *p* = 0.008), 30-day mortality (17% vs. 27%, *p* = 0.007), and one-year mortality (34% vs. 46%, *p* = 0.006). The incidence of long-term ventilator and dialysis dependence did not differ between groups.

10.1371/journal.pone.0233178.t002

###### Various outcomes according to troponin I level.

dx.doi.org/10.17504/protocols.io.bfbhjij6.

![](pone.0233178.t002){#pone.0233178.t002g}

                                     Overall (n = 597)   Troponin I ≤ 0.1 (n = 190)   Troponin I \> 0.1 (n = 407)   *P* value
  ---------------------------------- ------------------- ---------------------------- ----------------------------- -----------
  **Short-term outcomes**                                                                                           
      Length of ICU stay             11 ± 7.0            11 ± 7.2                     11 ± 7.0                      0.939
      Length of hospitalization      36 ± 37.2           38 ± 32.5                    36 ± 39.3                     0.510
      GI bleeding during admission   394 (66.1)          123 (65.1)                   271 (66.6)                    0.780
      AKI during admission (%)       243 (41)            76 (40)                      167 (41)                      0.858
      Hospital mortality (%)         209 (35)            52 (27)                      157 (39)                      0.008
      30-day mortality (%)           142 (24)            32 (17)                      110 (27)                      0.007
  **Long-term outcomes**                                                                                            
      Ventilator dependent (%)       33 (6)              10 (5)                       23 (6)                        1.000
      Dialysis dependent (%)         64 (11)             16 (8)                       48 (12)                       0.256
      One-year mortality (%)         251 (42)            64 (34)                      187 (46)                      0.006

Values are given as mean and standard deviation or numbers and percentages.

GI, gastrointestinal; AKI, acute kidney injury

The survival rates of patients, stratified by troponin I level, are shown in [Fig 2](#pone.0233178.g002){ref-type="fig"}. The 30-day and one-year all-cause mortality rates were significantly higher in patients with elevated troponin I level. In the multivariate Cox regression analysis of all patients admitted to ICU adjusted for the APACHE II score, diagnosis at admission, infection focus, serum lactate level, underlying disease with cancer, and chronic medication (beta-blockers and antithrombotics) use, troponin I \> 0.1 ng/mL was associated independently with one-year mortality ([Table 3](#pone.0233178.t003){ref-type="table"}).

![Kaplan-Meier curve for all-cause mortality according to troponin I level at ICU admission (A) 30-day all-cause mortality (B) one-year all-cause mortality. [dx.doi.org/10.17504/protocols.io.bfbqjimw](https://dx.doi.org/10.17504/protocols.io.bfbqjimw).](pone.0233178.g002){#pone.0233178.g002}

10.1371/journal.pone.0233178.t003

###### Multivariate analysis of risk of one-year mortality of all patients by a Cox regression model.
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                                 Univariate analysis              Multivariate analysis   
  ------------------------------ ---------------------- --------- ----------------------- ---------
  Age (year)                     1.003 (0.995--1.010)   0.469                             
  Sex (male)                     1.161 (0.893--1.509)   0.264                             
  APACHE II                      1.064 (1.047--1.081)   \<0.001   1.062 (1.042--1.083)    \<0.001
  SOFA                           1.123 (1.081--1.166)   \<0.001                           
  Admission diagnosis                                                                     
      Respiratory failure        \-                     \-        \-                      \-
      hemodynamic unstable       1.348 (1.036--1.755)   0.026     1.225 (0.907--1.655)    0.185
      Post operation             0.367 (0.230--0.586)   \<0.001   0.569 (0.340--0.952)    0.032
  Focus of infection                                                                      
      Pneumonia                  1.604 (1.248--2.061)   \<0.001   1.458 (1.080--1.968)    0.014
      Bacteremia                 1.208 (0.829--1.759)   0.326                             
      Intraabdominal infection   0.910 (0.640--1.296)   0.602                             
  Lab findings                                                                            
      Troponin I \>0.1 (ng/ml)   1.568 (1.180--2.083)   0.002     1.516 (1.096--2.095)    0.012
      Serum creatinine (mg/dl)   0.967 (0.910--1.027)   0.277                             
      HCO3                       1.020 (0.995--1.046)   0.118                             
      Lactate (mg/dl)            1.005 (1.001--1.009)   0.028     0.997 (0.992--1.003)    0.357
      CRP (mg/dl)                0.991 (0.973--1.010)   0.347                             
  Underlying disease                                                                      
      Hypertension               0.917 (0.716--1.175)   0.493                             
      Diabetes mellitus          0.898 (0.693--1.164)   0.417                             
      ESRD                       0.957 (0.633--1.447)   0.837                             
      CHF                        1.280 (0.916--1.789)   0.148                             
      CAD                        0.907 (0.662--1.243)   0.543                             
      CVD                        0.673 (0.406--1.117)   0.126                             
      Cancer                     1.428 (1.092--1.868)   0.009     1.684 (1.252--2.265)    0.001
  ACEI/ARB, chronic              0.961 (0.719--1.285)   0.788                             
  Beta-blocker, chronic          0.519 (0.360--0.749)   \<0.001   0.600 (0.392--0.917)    0.018
  Statin, chronic                0.767 (0.514--1.143)   0.193                             
  OHA, chronic                   1.018 (0.741--1.397)   0.914                             
  ATT, chronic prescription      0.574 (0.417--0.790)   0.001     0.639 (0.446--0.916)    0.015
  ATT, new prescription          0.898 (0.582--1.385)   0.626                             

HR, hazard ratio; CI, confidence interval; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; CRP, C reactive protein; ESRD, end stage renal disease; CHF, congestive heart failure; CAD, coronary artery disease; CVD, cerebrovascular disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; OHA, oral hypoglycemic agent; ATT, anti-thrombotics; ICU, intensive care unit.

Antithrombotic use during ICU stays in patients with troponin I elevation {#sec014}
-------------------------------------------------------------------------

In 407 patients with elevated troponin I, 273 (67%) patients were not on antithrombotics while 100 (25%) patients were on chronic prescription and 34 (8%) patients on new prescription during ICU admission. Patients using chronic antithrombotics were older, with higher prevalence of hypertension, diabetes mellitus, congestive heart failure, coronary artery disease (CAD) and concomitant medication with angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta blocker, statin and oral hypoglycemic agents. Patients received new prescription showed higher level of initial troponin I. No difference was observed in the percentages of ICU admission causes, infection focus, or serum parameters other than troponin I (including the blood urea nitrogen level; platelet count; pH; and bicarbonate, lactate, and C-reactive protein levels among three groups ([Table 4](#pone.0233178.t004){ref-type="table"}). Subsequent coronary revascularization was performed highest in patients with chronic antithrombotic medication although statistically not significant. The lengths of ICU stay and hospitalization did not differ among three groups; neither did the occurrence of in-hospital gastrointestinal tract bleeding or AKI; in-hospital, 30-day; or ventilator and dialysis dependence. However, one-year mortality was found to be significantly lower in patients with chronic prescription of antithrombotic medication ([Table 5](#pone.0233178.t005){ref-type="table"}). In cox regression model in patients with elevated troponin I, chronic antithrombotic treatment was associated with lower one-year all-cause mortality after adjusting age, gender, APACHE score, SOFA score, ICU admission diagnosis of shock or post operation status, focus of infection (pneumonia), initial serum lactate level, co-morbidities (tumor), co-administration of long term medication (beta blocker). ([Table 6](#pone.0233178.t006){ref-type="table"}) The 30-day and one-year survival rates in the troponin I elevation group, stratified by chronic and new prescription of antithrombotic are shown in [Fig 3](#pone.0233178.g003){ref-type="fig"}. These results showed a significant protective effect of chronic antithrombotic use for one-year survival (*p* = 0.008, log-rank test).

![Kaplan-Meier curve for all-cause mortality according to antithrombotics use during ICU admission (A) 30-day all-cause mortality (B) one-year all-cause mortality. [dx.doi.org/10.17504/protocols.io.bfbrjim6](http://doi.org/dx.doi.org/10.17504/protocols.io.bfbrjim6).](pone.0233178.g003){#pone.0233178.g003}

10.1371/journal.pone.0233178.t004

###### General features of the patients, according to medications in patients with elevated troponin I.
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                                       No prescription (n = 273)   Chronic prescription (n = 100)   New prescription (n = 34)   *P* value
  ------------------------------------ --------------------------- -------------------------------- --------------------------- -----------
  Age (year)                           67 ± 18                     76 ± 12                          69 ± 17                     0.0001
  Sex (male)                           171 (63)                    65 (65)                          20 (59)                     0.803
  APACHE II                            28 + 8                      28 + 8                           28 + 7                      0.853
  SOFA                                 9.7 + 3.5                   9.7 + 3.2                        9.3 + 3.2                   0.877
  Coronary revascularization (%)       17 (6)                      13 (13)                          1 (3)                       0.052
  Admission diagnosis                                                                                                           
      Respiratory failure (%)          144 (53)                    49 (49)                          14 (41)                     0.406
      hemodynamic unstable (%)         91 (33)                     34 (34)                          11 (32)                     0.983
      Post op (%)                      38 (14)                     16 (16)                          9 (27)                      0.160
  Focus of infection                                                                                                            
      Pneumonia (%)                    132 (48)                    47 (47)                          16 (47)                     0.968
      Catheter related infection (%)   34 (13)                     8 (8)                            6 (18)                      0.270
      Intraabdominal infection (%)     40 (15)                     12 (12)                          3 (9)                       0.566
  Lab findings, Mean ± SD                                                                                                       
      Troponin I (ng/ml)               1.36 + 2.81                 2.16 + 4.13                      5.40 + 11.4                 0.0001
      Serum creatinine (mg/dl)         2.8 + 2.2                   3.2 + 2.4                        2.2 + 1.2                   0.091
      HCO3 (mmHg)                      20.5 + 5.3                  20.5 + 4.6                       21.2 + 4.2                  0.756
      Lactate (mg/dl)                  31.1 + 31.7                 23.8 + 20.2                      22.4 + 24.0                 0.050
      CRP (mg/dl)                      11 + 10                     16 + 12                          12 + 12                     0.106
  Underlying disease                                                                                                            
      Hypertension (%)                 136 (50)                    64 (64)                          14 (41)                     0.020
      Diabetes mellitus (%)            84 (31)                     55 (55)                          15 (44)                     0.0001
      COPD (%)                         14 (5)                      5 (5)                            1 (3)                       0.856
      ESRD (%)                         38 (14)                     10 (10)                          4 (12)                      0.594
      CHF (%)                          33 (12)                     25 (25)                          5 (15)                      0.009
      Prior history of CAD (%)         28 (10)                     43 (43)                          8 (24)                      0.0001
      Prior stroke (%)                 15 (6)                      12 (12)                          6 (18)                      0.013
      cancer (%)                       68 (25)                     17 (17)                          5 (15)                      0.147
  Chronic medication use                                                                                                        
      ACEI/ARB                         43 (16)                     40 (40)                          6 (18)                      0.0001
      Beta-blocker                     38 (14)                     35 (35)                          4 (12)                      0.0001
      Statin                           18 (7)                      37 (37)                          1 (3)                       0.0001
      OHA                              35 (13)                     44 (44)                          10 (29)                     0.0001

Values are given as mean and standard deviation or numbers and percentages.

APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; CRP, C reactive protein; COPD, chronic obstructive pulmonary disease; ESRD, end stage renal disease; CHF, congestive heart failure; CAD, coronary artery disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; OHA, oral hypoglycemic agent; ATT, antithrombotics; ICU, intensive care unit.

10.1371/journal.pone.0233178.t005

###### Outcomes according to medications in patients with elevated troponin I.
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                                     No prescription (n = 249)   Chronic prescription (n = 100)   New prescription (n = 34)   P value
  ---------------------------------- --------------------------- -------------------------------- --------------------------- ---------
  **Short-term outcomes**                                                                                                     
      Length of ICU stay             12 + 7                      11 + 7                           10 + 5                      0.276
      Length of hospitalization      36 + 37                     33 + 25                          46 + 75                     0.256
      GI bleeding during admission   178 (65)                    67 (67)                          24 (71)                     0.802
      AKI during admission           108 (40)                    45 (46)                          14 (41)                     0.594
      Hospital mortality (%)         113 (41)                    26 (26)                          17 (50)                     0.009
      30-days mortality (%)          76 (28)                     19 (19)                          13 (38)                     0.063
  **Long-term outcomes**                                                                                                      
      Ventilator dependent (%)       14 (5)                      6 (6)                            3 (9)                       0.669
      Dialysis dependent (%)         34 (13)                     12 (12)                          2 (6)                       0.532
      One-year mortality (%)         134 (49)                    34 (34)                          19 (56)                     0.017

Values are given as mean and standard deviation or numbers and percentages.

ICU, intensive care unit; GI, gastrointestinal; AKI, acute kidney injury.

10.1371/journal.pone.0233178.t006

###### Multivariate analysis of risk of one-year all-cause mortality of patients with elevated troponin I by a Cox regression model.
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                                   Univariate analysis    Multivariate analysis                          
  -------------------------------- ---------------------- ----------------------- ---------------------- --------
  Age (year)                       1.011 (1.002--1.020)   0.020                   1.008 (0.998--1.018)   0.106
  Sex (male)                       1.315 (0.971--1.781)   0.077                   1.293 (0.923--1.812)   0.136
  APACHE II                        1.057 (1.038--1.077)   0.0001                  1.051 (1.025--1.078)   0.0001
  SOFA                             1.089 (1.042--1.138)   0.0001                  1.021 (0.963--1.083)   0.491
  Admission diagnosis                                                                                    
      Respiratory failure          1.134 (0.850--1.512)   0.392                                          
      hemodynamic unstable         1.433 (1.067--1.924)   0.017                   1.012 (0.723--1.418)   0.944
      Post operation               0.345 (0.196--0.606)   0.0001                  0.439 (0.231--0.835)   0.012
  Focus of infection                                                                                     
      Pneumonia                    1.575 (1.179--2.105)   0.002                   1.182 (0.843--1.657)   0.331
      Bacteremia                   1.172 (0.769--1.787)   0.459                                          
      Intraabdominal infection     1.000 (0.656--1.524)   1.000                                          
  Lab findings                                                                                           
      Initial troponin I (ng/ml)   1.018 (0.987--1.050)   0.248                                          
      Serum creatinine (mg/dl)     0.938 (0.873--1.008)   0.080                                          
      HCO3                         1.028 (0.998--1.059)   0.065                                          
      Lactate (mg/dl)              1.005 (1.000--1.009)   0.047                   1.000 (0.994--1.005)   0.970
      CRP (mg/dl)                  0.981 (0.959--1.004)   0.105                                          
  Underlying disease                                                                                     
      Hypertension                 1.012 (0.759--1.348)   0.937                                          
      Diabetes mellitus            0.904 (0.671--1.217)   0.505                                          
      ESRD                         0.927 (0.594--1.446)   0.738                                          
      CHF                          1.253 (0.864--1.817)   0.234                                          
      CAD                          0.866 (0.619--1.211)   0.401                                          
      CVD                          0.791 (0.459--1.363)   0.398                                          
      Cancer                       1.487 (1.077--2.052)   0.016                   1.528 (1.086--2.152)   0.015
  ACEI/ARB, chronic                0.983 (0.695--1.390)   0.922                                          
  Beta-blocker, chronic            0.521 (0.339--0.800)   0.003                   0.625 (0.395--0.988)   0.044
  Statin, chronic                  0.688 (0.432--1.094)   0.114                                          
  OHA, chronic                     0.843 (0.586--1.213)   0.357                                          
  Antithrombotic medication                                                                              
      Chronic vs. no               0.584 (0.401--0.851)   0.005                   0.595 (0.391--0.906)   0.015
      New vs. no                   1.198 (0.741--1.937)   0.462                   1.260 (0.742--2.140)   0.392
      Chronic vs. new              0.487 (0.278--0.855)   0.012                   0.472 (0.256--0.869)   0.016

HR, hazard ratio; CI, confidence interval; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; CRP, C reactive protein; ESRD, end stage renal disease; CHF, congestive heart failure; CAD, coronary artery disease; CVD, cerebrovascular disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; OHA, oral hypoglycemic agent

Discussion {#sec015}
==========

This study demonstrated that elevated troponin I at the time of ICU admission in the absence of ACS was associated with higher 30-day and one-year mortality. For patients with elevated troponin I levels, new antithrombotic prescriptions during ICU stay were not associated with 30-day or 1-year survival benefit whereas chronic antithrombotic use was related to better one-year survival. Although troponin I is a relevant biomarker for the diagnosis of AMI, troponin I elevation may be related to other conditions, such as heart failure, renal failure, left ventricular hypertrophy, and severe sepsis. \[[@pone.0233178.ref013]\] These conditions increased myocardial oxygen demand from elevated left ventricular end diastolic pressure, tachyarrhythmia or anemia. However, in patients with previous stable coronary artery disease, there was insufficient blood flow to meet increased myocardial oxygen demand which subsequently lead to myocardial injury. \[[@pone.0233178.ref014]\] Troponin I elevation was found in approximately 43% of patients admitted to non-cardiac ICUs in previous studies. \[[@pone.0233178.ref003]\] Troponin I elevation was more prevalent in our study, which can be explained by the difference in disease severity between our population and those reported on previously (mean APACHE II and SOFA scores were 27 and 9 in our study).

In-hospital and long-term prognostic impacts of troponin I elevation in these patients have been reported, and have been related in some, but not all, studies to poor prognosis. \[[@pone.0233178.ref003], [@pone.0233178.ref015], [@pone.0233178.ref016]\] We found that troponin I elevation was associated significantly with increased 30-day and one-year mortality. Moreover, Mohammed et al. \[[@pone.0233178.ref017]\] reported that troponin I elevation was associated with prolonged mechanical ventilation. Differences among studies are attributable to the inclusion of only patients with severe sepsis and septic shock in previous studies, whereas our study population comprised all patients admitted to the non-cardiac ICU with various medical and surgical conditions. Patients in elevated troponin I group had more complex disease status (i.e., higher APACHE II scores, advanced shock) and multiple co-morbidities (e.g., congestive heart failure, poorer renal function) relative to those without troponin I elevation. Our multivariate analysis showed that poorer prognosis was independent of the APACHE II score, serum lactate level, underlying diseases (e.g., prior stroke, cancer), and prescription of beta-blockers and chronic antithrombotic agents.

Nathaniel et al. \[[@pone.0233178.ref018]\] reported that only 10% of patients with sepsis and elevated troponin I levels underwent invasive procedures, such as coronary angiography, of whom 39% received coronary revascularization with percutaneous coronary intervention or bypass surgery. That real-world, nationwide study reflects daily clinical practice. Most cardiologists commonly defer invasive management for patients with elevated troponin I levels with no clinical symptom, sign, or electrocardiographic evidence, primarily when type 2 MI is highly suspected. In our study, 8% of patients with elevated troponin I levels underwent coronary angiography and revascularization.

Medical therapy may be the mainstay of treatment for patients with type 2 MI. In the CURE study, combination therapy with aspirin and clopidogrel or ticagrelor resulted in well-established reductions in cardiovascular death and MI recurrence in patients with AMI, regardless of coronary revascularization receipt. \[[@pone.0233178.ref007], [@pone.0233178.ref019]\] Anti-coagulants such as low-molecular-weight heparin, enoxaparin, and unfractionated heparin further reduced the occurrence of adverse events. \[[@pone.0233178.ref020]\] However, the efficacy of these medications in patients with type 2 MI remains uninvestigated. Saraschandra et al. found that on-admission and delta troponin T levels were independent predictors of in-hospital and 1-year survival. Prior aspirin use in these patients did not change in-hospital or long-term mortality in analyses adjusted for age, sex, BMI, Charlson comorbidity index, APACHE III score, AKI, and respiratory failure. \[[@pone.0233178.ref021]\] The Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy trial showed that patients with insignificant CAD are unlikely to benefit from glycoprotein IIb/IIIa therapy. \[[@pone.0233178.ref022]\] In ARRIVE trial, aspirin failed to reduce major cardiovascular events for primary prevention in patients with moderate cardiovascular risk as increased risk of bleeding. \[[@pone.0233178.ref023]\]

However, chronic antithrombotic medication reduced one-year all-cause mortality in patients with elevated troponin I levels. It may be partially explained by protective effect of these medication on the underlying diseases. Atrial fibrillation increased risk of stroke and sudden cardiac death in general population and those with history of coronary artery disease, myocardial infarction and heart failure. \[[@pone.0233178.ref024]\] In previous meta-analysis, warfarin reduced risk of stroke and thromboembolic complication from atrial fibrillation compared to non-warfarin user and direct oral anticoagulation was superior to warfarin in prevention of stroke. \[[@pone.0233178.ref025]\] Subsequently, these anticoagulants lowered all-cause mortality in patients with atrial fibrillation possibly from preventing fatal ischemic stroke. \[[@pone.0233178.ref026], [@pone.0233178.ref027]\] Antiplatelet agents such as aspirin, Plavix, prasugrel and ticagrelor were found to have protective effect in patients with known occlusive vascular events such as myocardial infarction, ischemic stroke and peripheral arterial disease. These medications lowered risk of further major adverse cardiovascular events which may reduce all-cause mortality. \[[@pone.0233178.ref006], [@pone.0233178.ref028]\]

In a previous study, 4.7% of patients admitted to the ICU developed at least one episode of overt gastrointestinal bleeding, and 2.6% experienced clinically important gastrointestinal bleeding which subsequently increased risk of mortality. \[[@pone.0233178.ref029], [@pone.0233178.ref030]\] However, prevalence of overt gastrointestinal bleeding was not altered by treatment of aspirin or anticoagulant medication during ICU stay in previous cohort study (Odd ratio: 0.76, 95% CI: 0.35--1.64) and (Odd ratio: 2.05, 95% CI: 0.89--4.73) respectively as coagulopathy, acute kidney injury or co-existing liver disease were independent risk factors for clinically important GI bleeding in these patients apart from adverse effect of anticoagulant. \[[@pone.0233178.ref029]\] Nevertheless, the occurrence of gastrointestinal bleeding did not differ between patients treated with and without antithrombotics in our study, preventing examination of the potential for this factor to confound the primary outcome of all-cause mortality.

Our study has several limitations. It was retrospective and conducted at a single medical center. In addition, it was conducted in a non-cardiac ICU, where blood samples were not submitted for troponin I detection for all patients, which may have introduced selection bias. We included a diverse group of patients, in whom troponin I elevation may not have been related to obstructive CAD. In addition, a relatively small percentage of patients in our study underwent invasive coronary revascularization, which might have influenced the outcomes. Moreover, medication use in these critically ill patients may have been limited by coexisting medical conditions, as physicians may hesitate to prescribe antithrombotic agents, especially to patients with active gastrointestinal bleeding.

Conclusion {#sec016}
==========

Troponin I elevation at the time of non-cardiac ICU admission was associated with higher short-term and long-term mortality in critically ill patients. New prescription of antithrombotic medication to patients with elevated troponin I levels during their ICU stays showed no benefit, but chronic antithrombotic agent use was associated with a better one-year survival rate, suggesting that these drugs play a protective role in this high-risk population.

10.1371/journal.pone.0233178.r001
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5\. The authors do not clearly report whether any of their patients subsequently underwent echocardiography, stress testing, coronary angiography or PCI and these data should be provided.

Discussion:

1\. Throughout, the authors should state that the different exposures (high troponin, receipt of antithrombotics) were ASSOCIATED with higher/lower mortality in this observational study, not using words or phrases that imply causation.

2\. In the second paragraph, the authors discuss at length potential causes of type 2 MI and non-MI troponin elevations, and this discussion should be shortened as it is not directly relevant to their main research hypothesis.

3\. The authors don't really explain why chronic antithrombotic use is associated with better outcomes---they suggest that it might be related to the underlying disease without proposing a plausible mechanism of benefit.

4\. The authors subsequently discuss GI bleeding at length even though this was unexpectedly not seen in their patients who received antithrombotics---this discussion should be shortened.
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Responses to reviewer 1

Thank you very much for your valuable comments which are very instructive and helpful to this manuscript and our future research. The responses to the comments were dictated below and all changes to manuscript which mark with track changes.

1\. Regarding the comment "The authors discuss Type 1 and type 2 MI at the end of the opening paragraph without defining these entities and emphasizing their differences. Then, at the beginning of the secondary paragraph, it is implied that obstructive CAD is the difference between type 1 and type 2 MI, which is not true per se. The authors should be consistent about these distinctions, and introduce the distinction between type 1 and 2 MI earlier in the manuscript."

Ans: Thank you for your comment. The main difference between type 1 and type 2 MI is the pathophysiology in which type 1 MI was thrombus identification by angiography or intracoronary imaging or by autopsy, and the type 2 MI was contributed by supply and demand mismatch. As you suggested, we had added more descriptions in the introduction section. (Please see the page 5 / line 67.)

2\. Regarding the comment "The authors state that the upper reference limit of their troponin I assay is 0.16, so why did they choose \>0.1 as their cut-off to define an elevated troponin. This should be justified, and the authors should use consistent terminology throughout the manuscript (detectable versus higher versus elevated). In addition, the brand/name of the assay should be provided."

Ans: Thank you for your comment. We agreed with you and corrected the mistake. We use the consistent terminology throughout the manuscript (all our data were based on troponin I \> 0.1 as in all other places). (Please see the revised table 1 and 2)

As you suggested, we provided the brand/name of the assay in the manuscript. (Please see the page 7/ line 126.)

3\. Regarding the comment "The authors define sepsis as an increase in the SOFA score - I presume this also requires the presence of known or suspected infection, and this should be stated explicitly."

Ans: Thank you for your comment. We had stated the definition according to the Third international consensus definition for sepsis and septic shock. (JAMA 2016; 315 (8): 801 -- 10). As you suggested, we mentioned this point in the revised Table 1.

4\. Regarding the comment "The authors do not state how they specifically excluded ACS patients, and this should be clarified."

Ans: Thank you for your comment. As you suggested, we excluded ACS patients in the current study and mentioned this point in the manuscript. (Please see the page 6/ line 85.)

5\. Regarding the comment "Propensity adjustment or inverse probability weighting would be a better method to account for the baseline differences between antithrombotic treatment groups".

Ans: Thank you for your comment. We agreed that propensity adjustment and inverse probability weighting are better methods in this situation. However, when considering the smaller number of patients in our study, we used the multivariate cox regression model to control baseline differences between the three groups. (Please see Table 6.)

6\. Regarding the comment "The section "Antithrombotic use during ICU stays in patients with troponin I elevation" is confusing in places. At times, all antithrombotics are considered together (chronic and new), and at other times these are separated. This should be stated more clearly."

Ans: Thank you for your comment. As you suggested, we divided the study patients with elevated troponin I to three groups according to the antithrombotic medications; patients with no prescription, chronic prescription, and new prescription during ICU stay. (Please see result section, page 8, line 133.)

7\. Regarding the comment "The statement "The lengths of ICU stay and hospitalization did not differ between the elevated and normal troponin I groups; neither did the occurrence of in-hospital gastrointestinal tract bleeding or AKI; in-hospital 30-day, or 1-year mortality; or ventilator and dialysis dependence (Table 5)" seems out of place here - by context, I presume the authors mean that the outcomes did not differ as a function of antithrombotic use but this should be clarified."

Ans: Thank you for your comment. As you suggested, the text is revised in Table 5. In previous cohort study (Intensive Care Med 2015; 41: 833 -- 845), overt and clinical important GI bleeding were not increased by treatment with aspirin and anticoagulant. Relevant explanation was added in the discussion section, page 17, line 325.

8\. Regarding the comment "The analyses should be clearly performed and stated comparing acute and chronic antithrombotic use.".

Ans: Thank you for your comment. As you suggested, we divided the study patients with elevated troponin I to three groups according to the antithrombotic medications; patients with no prescription, chronic prescription, and new prescription during ICU stay. We also performed the Kaplan Meier Survival curve to compare the three groups. (Please see Figure 3.)

9\. Regarding the comment "The section "Subgroup analysis of patients with detectable troponin I" likewise seems to be poorly named, as this examined the effects of several subgroups analyses and the results are not stated very clearly. If the authors' main finding is that patients with elevated troponin who were chronically on anticoagulants had lower mortality, but patients who were started on new antithrombotics did not then this should be clearly stated and appropriate analyses performed to demonstrate the point (and Figure 2 revised to show new vs. old antithrombotics)."

Ans: Thank you for your comment. We agreed with you and revised the Figure 3 to clearly stated this point. (Please see the revised Figure 3.)

10\. Regarding the comment "The authors do not clearly report whether any of their patients subsequently underwent echocardiography, stress testing, coronary angiography or PCI and these data should be provided."

Ans: Thank you for your comment. As you suggested, we provided the information in Table 4. We agreed with you that coronary revascularization might alter the prognosis in these patients, which we mentioned in the limitation section. (Please see the page 15/ line 274.)

11\. Regarding the comment "Throughout, the authors should state that the different exposures (high troponin, receipt of antithrombotics) were ASSOCIATED with higher/lower mortality in this observational study, not using words or phrases that imply causation."

Ans: Thank you for your comment. As you suggested, we have rephrased our description to a softer tune in result section. (Please see page 12, line 216.)

12\. Regarding the comment "In the second paragraph, the authors discuss at length potential causes of type 2 MI and non-MI troponin elevations, and this discussion should be shortened as it is not directly relevant to their main research hypothesis."

Ans: Thank you for your comment. We agreed with you and have shortened the paragraph in discussion section. (Please see page 13, line 248.)

13\. Regarding the comment "The authors don't really explain why chronic antithrombotic use is associated with better outcomes - they suggest that it might be related to the underlying disease without proposing a plausible mechanism of benefit."

Ans: Thank you for your comment. As you suggested, we have added more explanation in discussion section. (Please see page 16, line 306.)

14\. Regarding the comment "The authors subsequently discuss GI bleeding at length even though this was unexpectedly not seen in their patients who received antithrombotics - this discussion should be shortened."

Ans: Thank you for your comment. As you suggested, we have shortened the discussion section about GI bleeding accordingly. (Please see page 17, line 325.)

Thank you very much again! We appreciate your comments.
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